Combination chemotherapy as an adjuvant treatment in operable breast cancer. 1976

G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi

Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes. After 27 months of study, treatment occurred in 24 per cent of 179 control patients and in 5.3 per cent of 207 women given combination chemotherapy (P less than 10(-6)), the advantage appearing statistically significant in all subgroups of patients. Patients with four or more positive axillary nodes had a higher per cent of relapses than those with fewer nodes. The initial new clinical manifestations occurred in distant sites in 81.5 per cent of relapsed patients. Long-term chemotherapy produced an acceptable toxicity, thus allowing the administration of a high percentage of drug dosage. These results should be considered with caution, since, at present, the effect of this therapy on survival and possible long-term side effects remain unknown.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008408 Mastectomy Surgical procedure to remove one or both breasts. Mammectomy,Mammectomies,Mastectomies
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation

Related Publications

G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
June 1984, Deutsche medizinische Wochenschrift (1946),
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
May 1978, Lancet (London, England),
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
January 1995, Anticancer research,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
December 1985, Journal of steroid biochemistry,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
May 1976, Journal of the South Carolina Medical Association (1975),
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
April 1974, Cancer,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
January 1977, Progress in clinical and biological research,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
May 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
November 1980, Virginia medical,
G Bonadonna, and E Brusamolino, and P Valagussa, and A Rossi, and L Brugnatelli, and C Brambilla, and M De Lena, and G Tancini, and E Bajetta, and R Musumeci, and U Veronesi
January 2008, Anales de medicina interna (Madrid, Spain : 1984),
Copied contents to your clipboard!